{"publication_id":"767dd1a7-1300-4f73-8821-ca5a468dbafd","content_hash":"sha256:4ec7e520c621fabde58a8862734f7b29efe8f8fd8f455bc02feec1e3d84540bc","nodes":[{"id":"767dd1a7-1300-4f73-8821-ca5a468dbafd","type":"publication","title":"Bounded Semaglutide once signal: semaglutide (1.8%) versus placebo (2.2%)"},{"id":"claim_1","type":"claim","text":"The cited direct receipts support a bounded working claim: semaglutide (1.8%) versus placebo (2.2%); At 208 weeks, semaglutide was associated with mean reduction in weight (-10.2%) versus placebo (-1.5%; P < 0.0001)."},{"id":"claim_2","type":"claim","text":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication."},{"id":"claim_3","type":"claim","text":"_Evidence-map boundary: cited receipts are separate evidence streams unless an integrated analysis is explicitly stated; this memo maps a testable contrast, not a pooled meta-analysis or settled conclusion._"},{"id":"claim_4","type":"claim","text":"Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?"},{"id":"claim_5","type":"claim","text":"_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._"},{"id":"claim_6","type":"claim","text":"_Interpretation boundary: this is a hypothesis-generating alpha map, not confirmatory evidence or a settled conclusion. The heterogeneity matters because it routes the next test to the specific population, endpoint, comparator, and time window that can replicate, rather than letting a broad topic-level effect claim leak across mismatched receipts._"},{"id":"source_1","type":"source","study":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","year":2024,"doi":"10.1038/s41591-024-03015-5","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","year":2024,"doi":"10.1038/s41591-024-02996-7","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_3","type":"source","study":"Semaglutide for the treatment of overweight and obesity: A review","year":2022,"doi":"10.1111/dom.14863","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_4","type":"source","study":"Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial","year":2024,"doi":"10.2337/dc24-0491","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","year":2024,"doi":"10.1016/j.amjcard.2024.04.041","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"}],"edges":[{"from":"767dd1a7-1300-4f73-8821-ca5a468dbafd","to":"claim_1","type":"contains_claim"},{"from":"767dd1a7-1300-4f73-8821-ca5a468dbafd","to":"claim_2","type":"contains_claim"},{"from":"767dd1a7-1300-4f73-8821-ca5a468dbafd","to":"claim_3","type":"contains_claim"},{"from":"767dd1a7-1300-4f73-8821-ca5a468dbafd","to":"claim_4","type":"contains_claim"},{"from":"767dd1a7-1300-4f73-8821-ca5a468dbafd","to":"claim_5","type":"contains_claim"},{"from":"767dd1a7-1300-4f73-8821-ca5a468dbafd","to":"claim_6","type":"contains_claim"}],"screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}